Ipamorelin and sermorelin are both studied for raising growth hormone, but they pull different levers. Sermorelin is a GHRH analogue that works upstream on the pituitary; ipamorelin is a selective ghrelin-receptor (GHSR) agonist that fires a sharper GH pulse downstream. That difference is exactly why researchers often study them together. Both are supplied by New-U strictly for laboratory research — not for human use.
Sermorelin tells the pituitary to release more of its own growth hormone, on its own schedule, by mimicking growth-hormone-releasing hormone (GHRH 1-29). Ipamorelin mimics ghrelin instead, hitting the GHSR (growth-hormone-secretagogue) receptor to trigger a distinct, well-defined GH pulse — without the cortisol, prolactin or hunger spikes that the older GHRP-2 and GHRP-6 cause.
| Sermorelin | Ipamorelin | |
|---|---|---|
| Class | GHRH analogue (GHRH 1-29) | Selective ghrelin / GHSR agonist (GHRP) |
| Receptor | GHRH receptor (pituitary) | GHSR-1a (pituitary + hypothalamus) |
| GH-release shape | Amplifies the natural physiologic pulse; lower peak | Sharper, more discrete pulse; higher peak |
| Feedback preserved? | Yes — somatostatin still caps output | Largely, via a different pathway |
| Cortisol / prolactin | Minimal | Minimal (its headline selectivity advantage) |
| Appetite effect | None notable | Weak (far less than GHRP-6) |
| Half-life | ~10-20 min | ~2 hours |
| Typical research framing | Restore a natural nocturnal GH rhythm | Drive a clean, measurable GH pulse |
A GHRH signal (sermorelin) and a ghrelin signal (ipamorelin) reach the somatotroph by two different pathways, and when both arrive at once the GH release is larger than either alone — the classic CJC-1295 + ipamorelin pairing exploits the same synergy with a longer-acting GHRH analogue. Sermorelin's role is to keep the release physiologic and feedback-controlled; ipamorelin's is to make the pulse sharp and selective.
If the goal is to model a more natural, pituitary-driven GH rhythm with intact feedback, sermorelin is the cleaner probe. If the goal is a defined, repeatable GH pulse with minimal confounding cortisol/prolactin, ipamorelin is the more selective tool. Neither is "stronger" in the abstract — they answer different questions, which is why the literature treats them as complementary rather than competing.
Is ipamorelin or sermorelin better?
Neither universally — they act on different receptors. Sermorelin prompts the pituitary upstream (GHRH); ipamorelin fires a sharper pulse downstream (GHSR) with almost no cortisol or prolactin. The two are often combined because the mechanisms are complementary. Both sold for research use only.
What is the difference between ipamorelin and sermorelin?
Sermorelin is a GHRH 1-29 analogue that amplifies the pituitary's own GH rhythm; ipamorelin is a selective ghrelin/GHSR agonist that produces a stronger, more discrete pulse without raising cortisol, prolactin or appetite. Different receptor, different release shape.
Can you stack ipamorelin and sermorelin together?
In research, yes — a GHRH analogue plus a ghrelin-receptor agonist gives supra-additive GH release because the two signals converge through separate pathways. Co-studied as a research model only, not a human-use protocol.
Which has fewer side effects?
Both are "clean" relative to older secretagogues. Sermorelin keeps GH within physiologic limits via somatostatin feedback; ipamorelin's selectivity means negligible cortisol/prolactin. Reported study effects are mostly mild injection-site reactions. Neither is an approved medicine.
New-U supplies both as sealed 10-vial packs of lyophilised reference peptide, independently HPLC-verified at >99% purity by Janoshik and Freedom Diagnostics, with a per-batch Certificate of Analysis. Research use only — not for human consumption.
View Ipamorelin